Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PALI 
Palisade Bio Inc (PALI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PALI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.63% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.61M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 3 | Beta 1.39 | 52 Weeks Range 0.53 - 4.32 | Updated Date 09/17/2025 |
52 Weeks Range 0.53 - 4.32 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.59% | Return on Equity (TTM) -188.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 536857 | Price to Sales(TTM) 14.03 |
Enterprise Value 536857 | Price to Sales(TTM) 14.03 | ||
Enterprise Value to Revenue 234.89 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 9119150 | Shares Floating 8618237 |
Shares Outstanding 9119150 | Shares Floating 8618237 | ||
Percent Insiders 0.24 | Percent Institutions 5.92 |
Upturn AI SWOT
Palisade Bio Inc
Company Overview
History and Background
Palisade Bio, Inc. (previously known as Seneca Biopharma, Inc. and before that, BioForce Nanosciences Holdings, Inc.) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients suffering from acute and chronic gastrointestinal (GI) complications. The company was founded in 2006, and has since been focused on advancing its lead asset, PALI-210, for postoperative GI dysfunction. Recent milestones include completing Phase 2 studies and planning for Phase 3 trials.
Core Business Areas
- Drug Development: Palisade Bio focuses on developing and commercializing pharmaceutical products targeting gastrointestinal (GI) conditions. Their primary focus is PALI-210, an oral solution for the treatment of postoperative GI dysfunction.
Leadership and Structure
The leadership team includes Thomas Hallam, CEO; Timothy Schertz, CFO. The organizational structure is typical of a small biotech company, with functional departments focused on research and development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- PALI-210: PALI-210 is an oral solution targeting the reduction of post-operative GI complications such as adhesions. The drug is currently in clinical development. Market share data is not yet available as the product is not yet commercialized. Competitors would include drugs or treatments that address post-operative ileus or adhesions, although PALI-210's specific mechanism of action aims to prevent the underlying problem of adhesion formation rather than just treat its symptoms.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Demand for effective treatments for GI disorders is significant due to the prevalence of these conditions.
Positioning
Palisade Bio is positioning itself as a leader in the prevention of postoperative GI complications. Its competitive advantage lies in its novel approach to preventing adhesion formation with PALI-210.
Total Addressable Market (TAM)
The TAM for postoperative GI complications is estimated to be significant, considering the millions of surgeries performed annually worldwide. The total addressable market is estimated in the billions of dollars globally, and Palisade Bio aims to capture a portion of this market with PALI-210.
Upturn SWOT Analysis
Strengths
- Novel approach to preventing GI adhesions
- Targeting unmet medical need
- Potential for significant market opportunity
Weaknesses
- Limited financial resources
- Dependence on a single product candidate
- Clinical trial risks and regulatory hurdles
Opportunities
- Successful clinical trial outcomes for PALI-210
- Partnerships with larger pharmaceutical companies
- Expansion into new GI indications
Threats
- Competition from existing treatments
- Failure to obtain regulatory approval
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- JAZZ
- SHPG
Competitive Landscape
Palisade Bio's competitive advantage lies in its preventative approach to GI adhesions, but faces challenges from established companies with approved treatments for related GI conditions. Currently Palisade has no market share due to its drug still being in trial phases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing PALI-210 through clinical trials and securing financing to support its development.
Future Projections: Future growth is dependent on the successful completion of Phase 3 trials for PALI-210 and subsequent regulatory approval.
Recent Initiatives: Recent initiatives include focusing on initiating Phase 3 trials, presenting clinical trial data at scientific conferences, and seeking potential partnerships.
Summary
Palisade Bio is a development-stage biopharmaceutical company with a novel approach to preventing GI adhesions with PALI-210. Its success hinges on positive Phase 3 trial results and regulatory approval. The company faces challenges from limited resources and competition from established players. Securing partnerships and expanding into new indications would strengthen its position. The company's ability to manage cash flow and navigate clinical trial risks will be critical for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Palisade Bio Inc. SEC Filings
- Palisade Bio Inc. Investor Relations
- Industry Reports on GI Complications
- Competitor Company Information
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palisade Bio Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2006-12-20 | CEO, CFO & Director Mr. J. D. Finley | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.palisadebio.com |
Full time employees 8 | Website https://www.palisadebio.com | ||
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.